Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Completed No phase listed Observational Accepts healthy volunteers

Outcomes of Neonatal Acute Kidney Injury In Premature Infants

NCT02375854
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Disease
Interventions
Observation
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
1 Day to 5 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 26, 2026, 2:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT01109394
View directory record Official record
Conditions
Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks and older
Enrollment
6,035 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Orange, Florida • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Results available

Study of Renal Denervation in Patients With Heart Failure

NCT01954160
View directory record Official record
Conditions
Heart Failure
Interventions
Symplicity Renal Denervation
Device
Lead sponsor
Adrian Hernandez
Other
Eligibility
21 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 26, 2026, 2:55 PM EDT
Recruiting Not applicable Interventional

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT07187479
View directory record Official record
Conditions
Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
Interventions
Physiologic Insulin Resensitization (PIR)
Other
Lead sponsor
Well Cell Global
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

NCT04626479
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Vibostolimab/Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 2:55 PM EDT
Completed No phase listed Observational

Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens

NCT00836862
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Biologic specimens
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

NCT05267262
View directory record Official record
Conditions
Alport Syndrome, Focal Segmental Glomerulosclerosis
Interventions
R3R01
Drug
Lead sponsor
River 3 Renal Corp.
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Boca Raton, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

NCT00397488
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 26, 2026, 2:55 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

NCT00844662
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Fermagate, Sevelamer hydrochloride
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Hot Springs, Arkansas • Bakersfield, California • Lynwood, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

NCT01143246
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 26, 2026, 2:55 PM EDT
Active, not recruiting Not applicable Interventional

CTSN Embolic Protection Trial

NCT06027788
View directory record Official record
Conditions
Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Interventions
CardioGard Embolic Protection Cannula, Standard Aortic Cannula
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years and older
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
North Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 26, 2026, 2:55 PM EDT
Recruiting Phase 3 Interventional

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
16
States / cities
Glendale, Arizona • San Diego, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer

NCT00446368
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
RAD001
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

NCT01763190
View directory record Official record
Conditions
Renal Impairment
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT01975818
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY 85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Azusa, California • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Not applicable Interventional

24 Hour Use of the Wearable Artificial Kidney

NCT02280005
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
WAK Treatment
Device
Lead sponsor
Blood Purification Technologies, Inc.
Industry
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

NCT01764854
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
Interventions
AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

NCT02644941
View directory record Official record
Conditions
Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
Interventions
Human Acellular Vessel (HAV), ePTFE graft
Biological · Device
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 26, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

NCT04352205
View directory record Official record
Conditions
Plasma Cell Myeloma, Renal Failure
Interventions
Bortezomib, Daratumumab, Dexamethasone, Lenalidomide, Thalidomide
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

NCT01678794
View directory record Official record
Conditions
Cardiorenal Syndrome (CRS)
Interventions
Candesartan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 26, 2026, 2:55 PM EDT
Completed No phase listed Observational

Impact of Microvascular Inflammation on Kidney Allograft Outcome

NCT06496269
View directory record Official record
Conditions
Transplant;Failure,Kidney, Kidney Transplant Rejection
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
Not listed
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
7
States / cities
Los Angeles, California • Atlanta, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transplant Social Worker Support for Live Kidney Donation in African Americans

NCT02369354
View directory record Official record
Conditions
Kidney Disease
Interventions
TALKS Social Worker Intervention, Financial Assistance Intervention
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

NCT03506854
View directory record Official record
Conditions
Renal Impairment
Interventions
ISIS 681257
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 26, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 26, 2026, 2:55 PM EDT